Streetbeat News

Price Targets

LEN

Unusual options activity has been observed in Lennar (NYSE:LEN), with 17 strange trades detected. 41% of investors opened trades with bullish expectations, while 58% were bearish. Whales have been targeting a price range of $90 to $145 for Lennar over the last 3 months. Analysts have mixed opinions on the stock, with price targets ranging from $94 to $161.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 8:01 pm

CHRS

Coherus BioSciences shares are trading lower after Truist Securities maintained a Buy rating on the stock but lowered its price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 8:01 pm

TYGO

Tigo Energy shares are trading higher after Roth MKM and Craig-Hallum initiated coverage on the stock with Buy ratings and price targets of $21 and $28, respectively.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2023 | 7:57 pm

BUD

A large bearish position on Anheuser-Busch InBev (NYSE:BUD) has been spotted, with 13 puts totaling $435,127 and 1 call totaling $27,000. The overall sentiment of these big-money traders is 35% bullish and 64% bearish. Evercore ISI Group maintains an Outperform rating with a price target of $70.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 7:47 pm

ADBE

In the last quarter, Adobe (NASDAQ:ADBE) received 4 bullish, 9 somewhat bullish, and 7 indifferent analyst ratings. The average 12-month price target for Adobe is $498.95, with a high of $600.00 and a low of $415.00, increasing by 16.97% over the past month.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 7:02 pm

LLY

In the last quarter, Eli Lilly (NYSE:LLY) received 2 bullish, 18 somewhat bullish, and 1 indifferent rating from analysts. The average 12-month price target for the company is $459.9, up 9.2% from the previous average of $421.16.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 7:02 pm

MOH

In the last quarter, Molina Healthcare (NYSE:MOH) received 1 bullish, 3 somewhat bullish, 4 indifferent, and 1 somewhat bearish analyst ratings. The average 12-month price target is $340.89, a 3.07% decrease from the previous average of $351.67.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 7:01 pm

CYTK

In the last 3 months, 11 analysts have provided 12-month price targets for Cytokinetics (NASDAQ:CYTK), with an average price target of $56.82, a 6.24% decrease from the previous average of $60.60. The ratings include 7 bullish, 4 somewhat bullish, and no bearish opinions.

Portfolio Pulse from Benzinga Insights

June 20, 2023 | 7:00 pm

ABBV

RGNX

SRPT

Baird has initiated coverage on RegenXbio Inc (NASDAQ:RGNX) with an Outperform rating and a price target of $42, citing potential gains from AAV gene therapies resurgence. The analyst believes RegenXbio can be a leader in the AAV gene therapy space and that the market underappreciates the opportunity for its partnered ABBV-RGX-314 with AbbVie Inc (NYSE:ABBV). Regenx could also compete with Sarepta Therapeutic Inc's (NASDAQ:SRPT) SRP-9001 in the DMD market.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 6:43 pm

ACVA

Needham analyst Chris Pierce reiterated a Buy rating on ACV Auctions Inc. (NASDAQ:ACVA) and raised the price target to $23 from $20. ACVA is gaining momentum in the Upper Midwest, and dealer hesitancy to transact digitally has decreased. This could lead to market share gains for the company in multiple cities in the region.

Portfolio Pulse from Nabaparna Bhattacharya

June 20, 2023 | 6:34 pm